Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Follistatin-344 peptide icon, one bubble per amino acidFollistatin-34417 residues (approx.)GNCWLRQAKNGRCQVLYEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.

Follistatin-344

Beginner tier: 100 mcg, daily · preclinical extrapolation

90 min half-life·Injection

Also known as: FS-344, FS344, Follistatin 344

A peer-reviewed case series documented retinal damage in 11 bodybuilders after they injected this peptide (Dağ et al.)[1]. Follistatin-344 (FS-344) is a naturally occurring glycoprotein that traps myostatin and activin, two TGF-beta superfamily proteins that limit skeletal muscle growth. The dramatic numbers (194 to 327 percent muscle mass increases) all come from transgenic mice and AAV gene therapy with continuous expression. Injectable FS-344 has a 90-minute half-life, delivering brief suppression spikes rather than sustained inhibition. Community results remain highly inconsistent, and roughly half of commercial products have tested as mislabeled.

What Is Follistatin-344?

A case series documented retinal damage in eleven bodybuilders after follistatin-344 injections. That case series (Dağ et al., International Ophthalmology)[1] is the most important published safety data for anyone considering this peptide.

Follistatin-344 (FS-344) is a glycoprotein that binds and neutralizes myostatin (GDF-8) and activin A, both members of the TGF-beta superfamily. After injection, FS-344 gets cleaved into two active forms: FS-315 circulates in serum, while FS-288 binds tightly to cell surfaces in muscle tissue. Both forms physically trap myostatin before it reaches ActRIIB receptors on muscle cells.

The animal research is striking. Kota and colleagues showed long-term skeletal muscle growth in primates using AAV-delivered follistatin [2]. Gene therapy trials in Becker muscular dystrophy patients improved walking distance without serious adverse events [3]. Those results reflect continuous follistatin expression, not brief pharmacokinetic spikes from daily subcutaneous injection.

Community experience is mixed. With fewer than 20 dedicated Reddit threads, follistatin sits in the niche tier. Users who report gains describe acute muscle fullness and modestly improved recovery. Product authenticity dominates the conversation; a 2020 study found roughly 50 percent of commercial FS315/FS344 products were mislabeled. Legitimate recombinant follistatin, sold as a lab reagent, costs around $4,600 per mg. Research-grade products sell for $107 to $160 per mg. That price gap is telling you something.

No human randomized controlled trial exists for injectable FS-344. Dosing is extrapolated from primate studies and gene therapy research.

How Follistatin-344 Works

Follistatin operates as a molecular trap within the TGF-beta superfamily signaling network. Its primary target is myostatin (GDF-8). Activin A is the secondary target.

Both myostatin and activin normally bind to ActRIIB receptors on the surface of muscle cells. That binding activates SMAD2/3 transcription factors inside the cell. The SMAD2/3 pathway suppresses muscle protein synthesis and blocks satellite cell activation. Follistatin intercepts these ligands before they reach ActRIIB. The binding affinity is high enough that one follistatin molecule neutralizes one myostatin dimer completely.

After subcutaneous injection, FS-344 splits into two functional isoforms. FS-315 has moderate heparin-binding affinity and circulates through the bloodstream. FS-288 binds tightly to heparan sulfate proteoglycans on cell surfaces, concentrating effects locally in tissue. The FS-288 form also has stronger potential for FSH suppression because follistatin inhibits activin, which regulates FSH secretion.

What makes the animal data unusual is the type of growth. Transgenic mouse studies showed both hypertrophy (larger muscle fibers) and hyperplasia (more fibers). That combination is rare; most anabolic agents produce one or the other. Kota and colleagues confirmed long-term skeletal muscle gains in primates [2].

The 90-minute circulating half-life is the core limitation. Gene therapy delivers continuous follistatin expression. A daily subcutaneous injection gives a brief spike followed by rapid clearance. Whether repeated transient suppression produces the same downstream signaling as sustained inhibition remains an open question.

Follistatin-344 Benefits

  • Follistatin-344 benefits center on myostatin pathway inhibition and its downstream effects on muscle tissue.
  • Blocks myostatin signaling through direct binding at ActRIIB receptors, removing the primary molecular brake on skeletal muscle protein synthesis. Transgenic mouse models showed 194 to 327 percent muscle mass increases with sustained expression.
  • Inhibits activin A and activin B through a separate but parallel pathway. Blocking activin also activates satellite cells, the resident stem cells responsible for muscle repair and new fiber formation.
  • Gene therapy trials in Becker muscular dystrophy patients showed measurable improvement in walking distance [3]. Six patients tolerated AAV-delivered follistatin without organ pathology over the follow-up period.
  • The FS-315 isoform does not appear to disrupt reproductive hormone signaling based on available preclinical data. This differentiates follistatin from some other myostatin-targeting approaches that suppress the HPG axis.
  • Community users who report positive results describe acute muscle fullness and faster recovery between training sessions within the first 7 to 14 days.
  • Hair regrowth through Wnt/beta-catenin signaling is an emerging research area. Published data is preclinical only.

Follistatin-344: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Weak
Based on 6 key studies·Research only

No human RCT data for injectable FS-344.

Dosing studied: 100–200 mcg/day SC; no clinically established human dose
Read the evidence (key study, limitations)

Dramatic muscle mass increases (194–327%) are from transgenic mice and AAV gene therapy: continuous overexpression, not daily peptide injections. Brief 90-min pharmacokinetic spikes from SC dosing are pharmacologically distinct from sustained gene therapy expression. The only published human safety signal is a documented CSCR case series (a case series of 11 bodybuilders with CSCR after FS-344)[1], subsequently formally incorporated into ophthalmology literature (2025 Survey of Ophthalmology)[4].

Key Study

Dag et al. 2020, International Ophthalmology (PMID 32671599): CSCR case series of 11 bodybuilders after FS-344; Kota et al. 2009 (PMID 20368179): long-term skeletal muscle enhancement in primates

Limitations

Zero published human RCTs for injectable FS-344. All efficacy data is animal (transgenic/AAV) or extrapolated from gene therapy trials in DMD/BMD patients. PK half-life (~90 min) makes transient peptide injections pharmacologically unlike gene therapy. No dose-finding studies in humans.

Community Experience
Weak
3.0/5
Based on low: <20 dedicated Reddit threads

Results are highly inconsistent.

Community dosing: 100–200 mcg/day SC; emerging: 50 mcg IM pre-workout on training days only
Read the reports (what users report 3, common issues 5)

Product authenticity is the dominant concern: roughly half of commercial FS344 products were found mislabeled. The subset who report gains describe acute muscle fullness and modestly enhanced recovery rather than dramatic hypertrophy. Awareness of the CSCR/vision risk is growing in experienced communities.

What users report (3)
  • Acute muscle fullness (most consistently reported effect)
  • Improved recovery between training sessions
  • Theoretical myostatin inhibition supporting hypertrophy (primary rationale)
Common issues (5)
  • Extreme product authenticity risk: ~50% of commercial samples mislabeled in testing
  • Highly variable results; many users see no measurable change
  • Documented CSCR/vision risk (peer-reviewed, not anecdotal) increasingly recognized in community
  • High cost relative to uncertain and inconsistent outcomes
  • Modest effects without concurrent anabolics (common community assessment)
Partially Aligned

Science and community agree myostatin inhibition is the mechanism and that injectable FS-344 is pharmacologically distinct from gene therapy. They diverge on whether transient daily SC injections produce meaningful muscle gain: community has believers and skeptics; science has no confirmatory human data. The CSCR risk is the one area where published evidence and community awareness are converging.

Follistatin-344 Dosage Guide

ExtrapolatedDose extrapolated from primate studies and gene therapy research; no human clinical dosing established
LevelDose / InjectionFrequency
Beginner100 mcg
DailyTrack
Moderate200 mcg
DailyTrack
Aggressive200 mcg
DailyTrack
Note:

Reconstitution math for a 1 mg vial with 1.0 mL bacteriostatic water: each 0.1 mL (10 units on a U-100 insulin syringe) equals 100 mcg. Beginner dose is 10 units. Moderate dose is 20 units. Aggressive dose is 30 units.

Product authenticity is the thing most beginners miss with this peptide. Around half of commercial FS-344 samples have tested as mislabeled. Real recombinant follistatin, sold only as a lab reagent for research, runs about $4,600 per mg; research-grade products sell for $107 to $160 per mg. That gap should raise questions. Only independent, batch-specific HPLC or mass spectrometry COAs verify a vial. Generic in-house certificates are not verification.

Cycle 2 weeks on, 4 weeks off. Daily injection is required because the half-life is only 90 minutes; you can't skip days and expect accumulation. Insulin syringe (29 to 31 gauge) for accuracy at these volumes. Reconstitute by rolling the vial gently. Do not shake. Store reconstituted product at 2 to 8 degrees Celsius and use within 14 days.

Cycling Protocol

On Period
2 weeks
Off Period
4 weeks

Short cycles recommended due to limited long-term safety data. Some protocols extend to 4 weeks on.

Calculate your Follistatin-344 dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

Follistatin-344 Protocols by Goal

beginnerCommunity2 weeks on / 4 weeks off per cycle; most protocols run 2–3 cycles
Active cycle
Wk 1–2
100 mcg · Daily · Subcutaneous
Off period
Wk 3–6
0 mcg · None · N/A

Expected: Modest muscle fullness and potentially enhanced recovery if product is authentic; dramatic hypertrophy unlikely from brief PK spikes alone

Monitor: Baseline retinal exam strongly recommended before use. Report any visual distortion, blind spot, or central blurring immediately: these are CSCR symptoms.

How to Use Follistatin-344

  1. 1
    Step 1

    Reconstitute one 1 mg vial with 1.0 mL of bacteriostatic water. Direct the stream down the glass wall, not onto the powder. Swirl gently or roll between your palms. Never shake.

  2. 2
    Step 2

    Draw your dose with a U-100 insulin syringe (29 to 31 gauge). Beginner: 10 units = 100 mcg. Moderate: 20 units = 200 mcg. Aggressive: 30 units = 300 mcg.

  3. 3
    Clean the injection site with an alcohol swab

    Pinch a fold of skin on the abdomen or outer thigh.

  4. 4
    Step 4

    Insert the needle at a 45-degree angle into the subcutaneous fat layer. Inject slowly and steadily.

  5. 5
    Rotate injection sites each day

    Abdomen (at least 2 inches from the navel) and outer thigh are the standard rotation.

  6. 6
    Inject once daily at the same time

    Morning or pre-workout is the community preference.

  7. 7
    Step 7

    Store the reconstituted vial upright in the refrigerator at 2 to 8 degrees Celsius. Use within 14 days. Lyophilized (unreconstituted) vials store at room temperature up to 30 days, refrigerated up to 12 months, or at -20 degrees Celsius for long-term storage.

  8. 8
    Step 8

    Perform an Amsler grid self-check each morning before injecting. Cover one eye, look at the grid at arm's length, check for wavy lines, blind spots, or central distortion. If anything looks off, stop and see an ophthalmologist.

Alternative Routes

Subcutaneous (abdomen/thigh)

No dose adjustment: 100–200 mcg SC daily is the reference protocol

Use insulin syringe for accuracy at these low doses. Some users report persistent injection site lumps with repeated SC use in the same location: rotate sites rigorously.

Intramuscular (target muscle group)

Community protocols use same dose range (50–200 mcg) via IM. Lower-dose emerging protocol (50 mcg IM pre-workout) is IM-specific.

IM injection into the trained muscle is reported to reduce injection site reactions. No published pharmacokinetic comparison of IM vs SC for FS-344. Theoretical local concentration advantage is unproven.

Mixing your own vial? Use the Follistatin-344 reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

Follistatin-344 Stacking Protocols

Works With

Avoid

Myostatin antibodies (ACE-031, LY2495655)

Additive myostatin inhibition: cumulative suppression may produce excessive and unpredictable muscle growth, cardiac risk, and tendon strain. These are experimental compounds with significant safety profiles even alone.

Do not combine
Anabolic-Androgenic Steroids (AAS)

Compounded cardiovascular risk: both FS-344 (rapid muscle/cardiac hypertrophy) and AAS (LVH, dyslipidemia) carry cardiovascular load. Combined use substantially elevates cardiac risk.

SARMs (LGD-4033, RAD-140, etc.)

Compounded anabolic signaling with HPG axis suppression. FS-344 may suppress FSH via activin inhibition; combining with SARMs adds LH/FSH suppression and androgen receptor modulation.

TGF-beta pathway modulators (pirfenidone, nintedanib)

Unpredictable pathway interactions: follistatin works within the TGF-beta superfamily. TGF-beta modulators used clinically for fibrosis could have additive or antagonistic effects.

Estimated Cost

Generic / Research
$107–$160 per 1mg vial (research-grade market range, Apr 2026)

Pricing updated 2026-04-09

Follistatin-344 Side Effects

The most documented risk with follistatin-344 injection is central serous chorioretinopathy (CSCR), a condition where fluid accumulates under the retina and distorts central vision. Dağ and colleagues published a retrospective case series in International Ophthalmology [1] describing CSCR in 11 male bodybuilders after high-dose subcutaneous FS-344 injection (10 in one eye, 1 in both). A 2025 Survey of Ophthalmology review [4] formally incorporated this finding into mainstream ophthalmology literature. Repeat users in the case series developed recurrent episodes. Subretinal fluid resolved in approximately 2.3 months for single-injection cases.

Anyone with pre-existing retinal disease or a history of CSCR should not use follistatin. Period.

Symptoms of CSCR include blurred central vision, blind spots, color distortion, and wavy lines. These can appear during the active cycle or during the off period afterward. A daily Amsler grid self-check takes 60 seconds and catches early signs before damage progresses.

Injection site reactions are the most commonly reported community complaint. Redness, swelling, and mild pain at the injection site occur frequently. Persistent subcutaneous lumps happen when users fail to rotate sites. Switching from subcutaneous to intramuscular administration reduces these reactions based on community reports.

The safety profile beyond CSCR has large gaps. No long-term studies exist for repeated subcutaneous FS-344 injection in healthy humans. Myostatin is expressed in cardiac tissue; chronic suppression could theoretically affect cardiac muscle remodeling. Rapid skeletal muscle growth may outpace tendon and ligament adaptation. Myostatin-null animal models show brittle tendons relative to muscle mass.

Follistatin inhibits activin, which regulates FSH. Extended or repeated use may suppress FSH and affect fertility. FSH and LH blood work after each cycle is recommended for anyone going beyond a single cycle. Target ranges: FSH 1.5 to 12.4 IU/L, LH 1.7 to 8.6 IU/L (men).

A 2024 study [5] flagged follistatin's effect on vascular function through activin A inhibition. Baseline cardiovascular assessment (resting ECG, blood pressure) before multi-cycle use is a reasonable precaution.

Contraindications: active cancer or history of hormone-sensitive cancers, pregnancy or breastfeeding, cardiac conditions, and children or adolescents (growth plate concerns). Any visual disturbance means immediate cessation and ophthalmology evaluation. Do not wait for the off period.

Common Issues & Solutions

Vision changes (blurriness, central blind spot, color distortion): stop immediately and seek ophthalmology evaluation: CSCR is a documented peer-reviewed risk [1][4]. Do not resume.

No visible results after a full cycle: most likely explanation is counterfeit or underdosed product (~50% of commercial FS-344 samples have been found mislabeled). Check the COA against third-party testing references before running another cycle.

Injection site lumps/pain persisting > 72 hours: switch from SC to IM administration: community reports IM is better tolerated. Ensure bac water is sterile and technique is correct.

Tendon/joint pain during rapid strength or size increases: add BPC-157 and/or TB-500 to stack. Myostatin-null animal models show brittle tendons relative to muscle mass; this risk is extrapolated but mechanistically plausible.

FSH or libido changes after extended use: follistatin inhibits activin, which regulates FSH. Prolonged suppression may affect fertility axis. Check FSH/LH levels and consider a longer off period (6+ weeks).

Ask AI about this page

Ask AI for a second opinion on Follistatin-344 dosing and side effects

Contraindications

  • Active cancer or history of hormone-sensitive cancers
  • Pregnancy or breastfeeding
  • Cardiac conditions (theoretical risk from rapid muscle changes)
  • Children and adolescents (growth plate concerns)
  • History of subretinal fluid or macular pathology: follistatin activity may promote VEGF-related neovascularization per PMID 39933627 (2025 review)

Drug Interactions

  • Myostatin-targeting antibodies (additive effect, increased risk)
  • TGF-beta pathway modulators (unpredictable interactions)
  • Other anabolic agents including AAS and SARMs (compounded cardiovascular risk)
  • Compounded anabolic signaling with HPG axis suppression. FS-344 may suppress FSH via activin inhibition; combining with SARMs adds LH/FSH suppression and androgen receptor modulation.

Product Quality

Recommended Monitoring

TestWhenTarget
Retinal examination (OCT or dilated fundus exam)Before first cycle, after each cycle, and immediately if any visual symptom occursNo subretinal fluid on OCT; no central vision defects on Amsler grid
FSH / LHBaseline before first use; after each cycle for extended or repeat usersFSH: 1.5–12.4 IU/L (men); LH: 1.7–8.6 IU/L (men)
Amsler grid self-checkDaily during active phase: take 60 seconds each morning before injectingNot listed
Cardiovascular assessment (resting ECG, blood pressure)Baseline and after multi-cycle useNot listed
Retinal examination (OCT or dilated fundus exam)

CSCR (central serous chorioretinopathy) documented in a case series of 11 bodybuilders injecting FS-344 (PMID 32671599). Now formally incorporated in mainstream ophthalmology literature (PMID 39933627, Survey of Ophthalmology 2025). Repeat users develop recurrent CSCR.

FSH / LH

Follistatin inhibits activin A/B, which regulates FSH secretion. Prolonged or repeated use may suppress FSH and affect fertility. FS-288 isoform has higher tissue binding and greater potential for FSH suppression; FS-344 is cleaved to FS-288 in vivo.

Amsler grid self-check

Inexpensive, at-home screen for early CSCR. Look for wavy lines, blind spots, or central blurring. If positive, stop immediately and seek ophthalmology.

Cardiovascular assessment (resting ECG, blood pressure)

Rapid skeletal muscle hypertrophy can be accompanied by cardiac muscle changes. Myostatin is expressed in cardiac tissue; theoretical risk of cardiac remodeling with prolonged inhibition. Blood pressure: 2024 study (PMID 39300291) shows follistatin affects vascular function via activin A inhibition.

Follistatin-344 Before and After

Days 1-3

Myostatin binding begins within hours. No visible changes yet.

Week 1

Myostatin inhibition underway at molecular level. Possible increase in training recovery.

Week 2
end of first cycle

Increased muscle fullness and improved strength reported by users. First cycle ends: begin 4-week off period.

Cycle 2-3
weeks 7-12

Cumulative gains across multiple cycles. Most noticeable muscle growth if combined with resistance training.

What to Expect

Days 1 through 3: FS-344 begins binding myostatin and activin within hours of injection. Circulating myostatin drops during the roughly 90-minute active window after each dose. Nothing visible changes yet. Some users notice mild redness or warmth at the injection site. Start your daily Amsler grid check from day one.

Week 1: Repeated daily injections create brief windows of myostatin suppression. Whether those transient pulses add up to meaningful cumulative inhibition is unproven. Satellite cell activation is theoretically beginning at the molecular level. Some users describe modest improvement in muscle fullness or training recovery. The majority notice no visible change. Keep monitoring for injection site reactions and any visual disturbances.

Week 2, end of standard cycle: The most variable phase. A minority of users report muscle fullness or scale weight increases of 5 to 15 pounds. Most see modest or no measurable change. Extraordinary weight claims likely include glycogen loading and water retention, not actual new muscle tissue. No sustained myostatin suppression is expected given the 90-minute half-life. The first 2-week cycle ends; begin the 4-week off period.

Off period, weeks 3 through 6: Myostatin and activin levels normalize within days after the last injection. Any genuine hypertrophic gains (new myofibers) should be maintained with continued resistance training. Muscle fullness often fades as glycogen and water shifts normalize. CSCR subretinal fluid can first become symptomatic during the off period, not only during active dosing. A post-cycle retinal exam is recommended.

Cycles 2 through 3, week 7 onward: No published data exists on cumulative effects of injectable FS-344 across multiple cycles in humans. Antibody formation against exogenous follistatin is a theoretical risk after repeated exposure, though no human data confirms this. Users in the CSCR case series who injected repeatedly developed recurrent retinal episodes. Product authenticity remains the confounding variable across all cycles.

Detailed Timeline: Science vs Community

Days 1–3
Science

FS-344 binds myostatin and activin within hours. Circulating myostatin levels measurably reduced during the ~90-min active window post-injection.

Community

No perceptible changes. Some report mild injection site redness or warmth.

Week 1
Science

Repeated brief myostatin suppression pulses. Whether cumulative inhibition approximates sustained suppression is unproven. Satellite cell activation theoretically beginning.

Community

Possible modest increase in muscle fullness and pumps. Enhanced recovery between training sessions. Majority report no visible change.

Week 2 / End of standard cycle
Science

Continued transient myostatin inhibition. No sustained suppression expected given half-life. Some users may report glycogen/water retention shifts presenting as muscle fullness.

Community

The most variable phase. A minority report significant muscle fullness or scale weight increases (5–15 lbs). Most see modest or no change. Extraordinary claims likely include glycogen loading and water retention.

Off period (weeks 3–6)
Science

Myostatin and activin levels normalize within days after cessation. Any hypertrophic gains are maintained through training; no expectation of gains accumulating during off period.

Community

Muscle fullness often fades. Genuine hypertrophic gains (new myofibers) would be maintained with continued training. Watch for CSCR symptoms: retinal fluid can manifest during or after the cycle.

Cycle 2–3 (weeks 7+)
Science

No published data on cumulative FS-344 injectable effects in humans across cycles. Antibody formation to follistatin after repeated exposure is a theoretical risk (no human data).

Community

Cumulative gains reported by some with concurrent resistance training and caloric surplus. Product authenticity remains the confounding variable across all cycles. Repeat injection users in CSCR case series developed recurrent retinopathy.

Pharmacokinetics

Half-Life
1.5h
Bioavailability
SC: high (exact % not established in humans)
Tmax
1-2 hours
Data Confidence
low

Source: Estimated from PK modeling; FS-344 circulating half-life ~90 minutes

Pharmacokinetics: Active Dose Over Time

t½ = ~90 minutes

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
17
Sequence
GNCWLRQAKNGRCQVLY
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons

Who Should Consider Follistatin-344

  • Individuals seeking muscle growth beyond natural limits
  • Those experiencing age-related muscle loss (sarcopenia)
  • Researchers studying TGF-beta signaling pathways
  • Individuals interested in hair regrowth applications

Related Peptides

What Changed for Follistatin-344

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20266 Citations

References

  1. [1]Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series (Dag et al., Int Ophthalmol 2020) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Follistatin gene delivery enhances muscle growth and strength in nonhuman primates (Sci Transl Med 2009) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy (opens in a new tab)PubMed (opens in a new tab)Clinical Trial
  4. [4]Pharmacological associations of central serous chorioretinopathy (Surv Ophthalmol 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]Follistatin lowers blood pressure and improves vascular structure and function in essential and secondary hypertension (Kuganathan et al., Hypertens Res 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Room temperature up to 30 days, refrigerated up to 12 months, -20°C for long-term
After Reconstitution
Refrigerate at 2-8°C, use within 14 days
Temperature
2-8°C (36-46°F) after reconstitution

Frequently Asked Questions

Honestly, the impressive numbers (194-327% muscle mass increases) all come from transgenic mice or AAV gene therapy with continuous follistatin expression. Not daily SC injections. Injectable FS344 gives you brief 90-minute spikes of myostatin inhibition. Whether those transient peaks replicate sustained inhibition is an open question, and community results are inconsistent.

You mostly can't without mass spectrometry. A 2020 study found roughly half of commercially available FS315/FS344 supplements were mislabeled. Third-party HPLC COAs and product-specific community reports on r/steroids are the closest substitutes.

This one is documented, not anecdotal. A peer-reviewed case series (Dağ et al., International Ophthalmology, 2020) found central serous chorioretinopathy (CSCR), retinal damage that distorts vision, in 11 bodybuilders after follistatin-344 injections (10 in one eye, 1 in both). Repeat users got recurrent episodes. Fluid resolved in about 2.3 months for single-injection cases.

They're commonly combined since both target muscle growth, but there's a theoretical wrinkle: IGF-1 signaling and TGF-beta/activin pathways interact, and some research suggests IGF-1 may upregulate follistatin on its own anyway. No catastrophic interactions have been reported from stacking, but the combined cardiovascular and growth signaling load is substantial.

Three likely explanations: counterfeit or underdosed products, caloric surplus masquerading as muscle gain (myostatin inhibition does increase appetite, and water plus glycogen shifts look like rapid mass gain), and genuine individual variation in baseline myostatin levels and satellite cell responsiveness. Extraordinary claims deserve skepticism here.